Aug 18 (Reuters) - AzurRx BioPharma Inc :
* AZURRX BIOPHARMA ANNOUNCES POSITIVE TOPLINE DATA FOR PHASE 2 MS1819 COMBINATION THERAPY TRIAL IN CYSTIC FIBROSIS PATIENTS WITH SEVERE EXOCRINE PANCREATIC INSUFFICIENCY $(EPI)$
* AZURRX BIOPHARMA INC - MS1819 AND PERT COMBINATION THERAPY ACHIEVES PRIMARY AND SECONDARY OUTCOME MEASURE ENDPOINTS
* AZURRX BIOPHARMA INC - STUDY DATA INDICATES CLINICALLY MEANINGFUL IMPROVEMENT IN COEFFICIENT OF FAT ABSORPTION $(CFA)$ PRIMARY ENDPOINT
* AZURRX BIOPHARMA INC - 20-PATIENT STUDY SUGGESTS COMBINATION THERAPY MAY BENEFIT CYSTIC FIBROSIS PATIENTS WITH SEVERE EPI
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。